CD8A and neoplasm: Subcutaneous injection of ACM‐encapsulated tumour‐antigen‐peptides into tumour‐bearing mice resulted in improved priming of CD8+ T cells and increased generation of tumour‐antigen‐peptide specific CD8+ effector T cells.